Tags

Type your tag names separated by a space and hit enter

Effect of phylloquinone (vitamin K1) supplementation for 12 months on the indices of vitamin K status and bone health in adult patients with Crohn's disease.

Abstract

Although epidemiological findings support a role for vitamin K status in the improvement of bone indices in adult patients with Crohn's disease (CD), this needs to be confirmed in double-blind, randomised controlled trials (RCT) with phylloquinone (vitamin K1). By conducting two RCT, the present study aimed to first establish whether supplementation with 1000 μg of phylloquinone daily near-maximally suppresses the percentage of undercarboxylated osteocalcin in serum (%ucOC; marker of vitamin K status) in adult patients with CD currently in remission as it does in healthy adults and second determine the effect of supplementation with phylloquinone at this dose for 12 months on the indices of bone turnover and bone mass. The initial dose-ranging RCT was conducted in adult patients with CD (n 10 per group) using 0 (placebo), 1000 or 2000 μg of phylloquinone daily for 2 weeks. In the main RCT, the effect of placebo v. 1000 μg vitamin K/d (both co-administered with Ca (500 mg/d) and vitamin D3 (10 μg/d)) for 12 months (n 43 per group) on the biochemical indices of bone turnover (determined by enzyme immunoassay) and bone mass (determined by dual-energy X-ray absorptiometry) were investigated. At baseline, the mean %ucOC was 47 %, and this was suppressed upon supplementation with 1000 μg of phylloquinone daily ( - 81 %; P< 0·01) and not suppressed further by 2000 μg of phylloquinone daily. Compared with the placebo, supplementation with 1000 μg of phylloquinone daily for 12 months had no significant effect (P>0·1) on bone turnover markers or on the bone mass of the lumbar spine or femur, but modestly increased (P< 0·05) the bone mass of the total radius. Despite near maximal suppression of serum %ucOC, supplementation with 1000 μg of phylloquinone daily (with Ca and vitamin D3) had no effect on the indices of bone health in adult CD patients with likely vitamin K insufficiency.

Links

  • Publisher Full Text
  • Authors+Show Affiliations

    ,

    School of Food and Nutritional Sciences, University College Cork,Cork,Republic of Ireland.

    ,

    Department of Medicine,University College Cork,Cork,Republic of Ireland.

    ,

    Department of Medicine,University College Cork,Cork,Republic of Ireland.

    ,

    Department of Medicine,University College Cork,Cork,Republic of Ireland.

    ,

    Department of Medicine,University College Cork,Cork,Republic of Ireland.

    ,

    Department of Medicine,University College Cork,Cork,Republic of Ireland.

    School of Food and Nutritional Sciences, University College Cork,Cork,Republic of Ireland.

    Source

    The British journal of nutrition 112:7 2014 Oct 14 pg 1163-74

    MeSH

    Adolescent
    Adult
    Aged
    Bone Density
    Bone Remodeling
    Calcium
    Cholecalciferol
    Crohn Disease
    Dietary Supplements
    Double-Blind Method
    Female
    Humans
    Male
    Middle Aged
    Nutritional Status
    Placebos
    Vitamin K
    Vitamin K 1
    Vitamins

    Pub Type(s)

    Journal Article
    Randomized Controlled Trial
    Research Support, Non-U.S. Gov't

    Language

    eng

    PubMed ID

    25181575

    Citation

    O'Connor, Eibhlís M., et al. "Effect of Phylloquinone (vitamin K1) Supplementation for 12 Months On the Indices of Vitamin K Status and Bone Health in Adult Patients With Crohn's Disease." The British Journal of Nutrition, vol. 112, no. 7, 2014, pp. 1163-74.
    O'Connor EM, Grealy G, McCarthy J, et al. Effect of phylloquinone (vitamin K1) supplementation for 12 months on the indices of vitamin K status and bone health in adult patients with Crohn's disease. Br J Nutr. 2014;112(7):1163-74.
    O'Connor, E. M., Grealy, G., McCarthy, J., Desmond, A., Craig, O., Shanahan, F., & Cashman, K. D. (2014). Effect of phylloquinone (vitamin K1) supplementation for 12 months on the indices of vitamin K status and bone health in adult patients with Crohn's disease. The British Journal of Nutrition, 112(7), pp. 1163-74. doi:10.1017/S0007114514001913.
    O'Connor EM, et al. Effect of Phylloquinone (vitamin K1) Supplementation for 12 Months On the Indices of Vitamin K Status and Bone Health in Adult Patients With Crohn's Disease. Br J Nutr. 2014 Oct 14;112(7):1163-74. PubMed PMID: 25181575.
    * Article titles in AMA citation format should be in sentence-case
    TY - JOUR T1 - Effect of phylloquinone (vitamin K1) supplementation for 12 months on the indices of vitamin K status and bone health in adult patients with Crohn's disease. AU - O'Connor,Eibhlís M, AU - Grealy,Geraldine, AU - McCarthy,Jane, AU - Desmond,Alan, AU - Craig,Orla, AU - Shanahan,Fergus, AU - Cashman,Kevin D, Y1 - 2014/09/02/ PY - 2014/9/3/entrez PY - 2014/9/3/pubmed PY - 2014/12/15/medline SP - 1163 EP - 74 JF - The British journal of nutrition JO - Br. J. Nutr. VL - 112 IS - 7 N2 - Although epidemiological findings support a role for vitamin K status in the improvement of bone indices in adult patients with Crohn's disease (CD), this needs to be confirmed in double-blind, randomised controlled trials (RCT) with phylloquinone (vitamin K1). By conducting two RCT, the present study aimed to first establish whether supplementation with 1000 μg of phylloquinone daily near-maximally suppresses the percentage of undercarboxylated osteocalcin in serum (%ucOC; marker of vitamin K status) in adult patients with CD currently in remission as it does in healthy adults and second determine the effect of supplementation with phylloquinone at this dose for 12 months on the indices of bone turnover and bone mass. The initial dose-ranging RCT was conducted in adult patients with CD (n 10 per group) using 0 (placebo), 1000 or 2000 μg of phylloquinone daily for 2 weeks. In the main RCT, the effect of placebo v. 1000 μg vitamin K/d (both co-administered with Ca (500 mg/d) and vitamin D3 (10 μg/d)) for 12 months (n 43 per group) on the biochemical indices of bone turnover (determined by enzyme immunoassay) and bone mass (determined by dual-energy X-ray absorptiometry) were investigated. At baseline, the mean %ucOC was 47 %, and this was suppressed upon supplementation with 1000 μg of phylloquinone daily ( - 81 %; P< 0·01) and not suppressed further by 2000 μg of phylloquinone daily. Compared with the placebo, supplementation with 1000 μg of phylloquinone daily for 12 months had no significant effect (P>0·1) on bone turnover markers or on the bone mass of the lumbar spine or femur, but modestly increased (P< 0·05) the bone mass of the total radius. Despite near maximal suppression of serum %ucOC, supplementation with 1000 μg of phylloquinone daily (with Ca and vitamin D3) had no effect on the indices of bone health in adult CD patients with likely vitamin K insufficiency. SN - 1475-2662 UR - https://www.unboundmedicine.com/medline/citation/25181575/Effect_of_phylloquinone__vitamin_K1__supplementation_for_12_months_on_the_indices_of_vitamin_K_status_and_bone_health_in_adult_patients_with_Crohn's_disease_ L2 - https://www.cambridge.org/core/product/identifier/S0007114514001913/type/journal_article DB - PRIME DP - Unbound Medicine ER -